Supreme Court slams Centre over pharmaceutical pricing, demands accountability

The Supreme Court has launched a scathing critique of the Centre's handling of pharmaceutical pricing, challenging government representatives to explain the steep markups on essential medicines. During proceedings, the bench questioned the justification for what it described as exploitative pricing practices in the drug sector, signaling judicial concern over medication costs affecting ordinary citizens.

The court's intervention comes amid persistent complaints about medicine prices outpacing inflation and limiting access to treatment for a significant portion of India's population. The judiciary's strong language underscores mounting frustration with the regulatory framework governing pharmaceutical pricing and the government's enforcement mechanisms.

The Centre has been directed to provide a substantive response addressing the pricing concerns raised by the court. This development represents a significant moment in India's ongoing debate over balancing pharmaceutical innovation and industry profitability against the need for affordable healthcare access.

The Supreme Court's intervention is likely to intensify scrutiny of the National Pharmaceutical Pricing Authority's policies and implementation. Consumer advocacy groups and healthcare experts have long argued for stricter price controls to ensure medicines remain accessible to the broader population.